Tebipenem Pivoxil

本周药品注册受理数据，分门别类呈现，一目了然。(8.10-8.16） 新药上市申请 药品名称 企业 注册分类 受理号 盐酸阿氟色替片 上海齐鲁制药研究中心有限公司 1 CXHS2600117 盐酸阿氟色替片 上海齐鲁制药研究中心有限公司 1 CXHS2600116 吸附无细胞百(五组分)白破联合疫苗 康希诺生物股份公司 2.2 CXSS2600123 TJ101注射液 天境生物药业(杭州)股份有限公司 1 CXSS2600122 新药临床申请 药品名称 企业 注册分类 受理号 HRS-6093片 江苏恒瑞医药股份有限公司 1 CXHL2601003 HRS-4642注射液 上海恒瑞医药有限公司 1 CXHL2601002 HRS-6093片 江苏恒瑞医药股份有限公司 1 CXHL2601001 HRS-2329片 江苏恒瑞医药股份有限公司 1 CXHL2601007 HRS-2329片 江苏恒瑞医药股份有限公司 1 CXHL2601006 HRS-2329片 江苏恒瑞医药股份有限公司 1 CXHL2601005 HRS-2329片 江苏恒瑞医药股份有限公司 1 CXHL2601004 VC005凝胶 江苏威凯尔医药科技股份有限公司 1 CXHL2600996 VC005凝胶 江苏威凯尔医药科技股份有限公司 1 CXHL2600995 BC923注射液 北京博源润步医药研发有限公司 1 CXHL2601000 HTMC0658片 上海壹典医药科技开发有限公司 1 CXHL2600999 HTMC0658片 上海壹典医药科技开发有限公司 1 CXHL2600998 HTMC0658片 上海壹典医药科技开发有限公司 1 CXHL2600997 HH-1270片 华辉安健(北京)生物科技有限公司 1 CXHL2600987 HH-1270片 华辉安健(北京)生物科技有限公司 1 CXHL2600986 177Lu-FAP-VG11注射液 山东威智知科药业有限公司 1 CXHL2600985 LB220-D08缓释片 石家庄以岭药业股份有限公司 1 CXHL2600984 LB220-D08缓释片 石家庄以岭药业股份有限公司 1 CXHL2600983 注射用SPN01 北京声光纳医疗科技有限公司 1 CXHL2600981 SIGX1094R片 希格生科(深圳)有限公司 1 CXHL2600991 SIGX1094R片 希格生科(深圳)有限公司 1 CXHL2600990 SHCW-8602片 广东红珊瑚药业有限公司 1 CXHL2600989 SHCW-8602片 广东红珊瑚药业有限公司 1 CXHL2600988 90Y-NRT6020注射液 成都纽瑞特医疗科技股份有限公司 1 CXHL2600980 HRS-5346 片 山东盛迪医药有限公司 1 CXHL2600979 HRS-2189片 山东盛迪医药有限公司 1 CXHL2600978 HRS-2189片 山东盛迪医药有限公司 1 CXHL2600977 盐酸(R)-氯胺酮注射液 成都倍特药业股份有限公司 2.1;2.4 CXHL2600982 YR-2316吸入粉雾剂 扬子江药业集团有限公司 2.2 CXHL2600994 YR-2316吸入粉雾剂 扬子江药业集团有限公司 2.2 CXHL2600993 左氧氟沙星雾化吸入溶液 浙江百代医药科技有限公司 2.4 CXHL2600992 注射用MHB034C 明慧医药(上海)有限公司 1 CXSL2600867 GC012F注射液 亘喜生物科技(上海)有限公司 1 CXSL2600864 注射用RT036 上海偌妥生物科技有限公司 1 CXSL2600865 注射用SHR-9839(sc) 苏州盛迪亚生物医药有限公司 1 CXSL2600869 注射用HS-20093 上海翰森生物医药科技有限公司 1 CXSL2600866 ACE723 艾司博迪亚(上海)生物科技有限公司 1 CXSL2600859 注射用SAL012 信立泰(成都)生物技术有限公司 1 CXSL2600858 注射用SHR-8925 苏州盛迪亚生物医药有限公司 1 CXSL2600857 ZHB 103注射液 江苏众红生物工程创药研究院有限公司 1 CXSL2600862 HB0056注射液 上海华奥泰生物药业股份有限公司 1 CXSL2600863 FG-M108注射液 明济生物制药(北京)股份有限公司 1 CXSL2600860 SKB118注射液 四川科伦博泰生物医药股份有限公司 1 CXSL2600856 注射用SKB500 四川科伦博泰生物医药股份有限公司 1 CXSL2600855 重组柯萨奇病毒B3注射液 武汉博威德生物技术有限公司 1 CXSL2600852 KL002注射液 康霖生物科技(杭州)有限公司 1 CXSL2600854 ICP-B381 北京诺诚健华医药科技有限公司 1 CXSL2600849 CM551注射液 康诺亚生物医药科技有限公司 1 CXSL2600851 BJ045注射液(皮下注射) 上海宝济药业股份有限公司 1 CXSL2600848 阿得贝利单抗注射液 上海盛迪医药有限公司 2.2 CXSL2600868 RY001 注射用重组A型肉毒毒素(大肠杆菌) 成都锐翼生物科技有限公司 2.4 CXSL2600861 仿制药申请 药品名称 企业 注册分类 受理号 中长链脂肪乳/氨基酸(16)/葡萄糖(30%)注射液 沈阳海思科制药有限公司 3 CYHS2602011 盐酸精氨酸注射液 天圣制药集团股份有限公司 3 CYHS2602012 普瑞巴林缓释片 宜昌人福药业有限责任公司 3 CYHS2602018 普瑞巴林缓释片 宜昌人福药业有限责任公司 3 CYHS2602017 普瑞巴林缓释片 宜昌人福药业有限责任公司 3 CYHS2602016 米诺地尔泡沫剂 辰光(天津)制药有限公司 3 CYHS2602020 琥珀酸亚铁片 浙江前进药业有限公司 3 CYHS2601997 左氧氟沙星口服溶液 吉林省辉南长龙生化药业股份有限公司 3 CYHS2601992 甘油果糖氯化钠注射液 赤峰源生药业有限公司 3 CYHS2601988 艾地苯醌片 齐鲁制药有限公司 3 CYHS2602008 盐酸丁卡因凝胶 德全药品(江苏)股份有限公司 3 CYHS2601985 盐酸丁卡因凝胶 德全药品(江苏)股份有限公司 3 CYHS2601984 盐酸非索非那定片 北京四环科宝制药股份有限公司 3 CYHS2601983 盐酸非索非那定片 北京四环科宝制药股份有限公司 3 CYHS2601982 硫酸锌注射液 北京远方通达医药技术有限公司 3 CYHS2601980 生理氯化钠溶液 河北广祥医药科技有限公司 3 CYHS2601979 左羟丙哌嗪口服溶液 吉林省辉南长龙生化药业股份有限公司 3 CYHS2601978 阿莫西林胶囊 浙江昂利康制药股份有限公司 3 CYHS2601976 阿莫西林胶囊 浙江昂利康制药股份有限公司 3 CYHS2601975 盐酸甲氧氯普胺口服溶液 安徽茂康药业有限公司 3 CYHS2601968 枸橼酸托法替布口服液 岳阳新华达制药有限公司 3 CYHS2601966 厄贝沙坦氨氯地平片 杭州沐源生物医药科技股份有限公司 3 CYHS2601964 布瑞哌唑口崩片 合肥英太制药有限公司 3 CYHS2601963 布瑞哌唑口崩片 合肥英太制药有限公司 3 CYHS2601962 布瑞哌唑口崩片 合肥英太制药有限公司 3 CYHS2601961 注射用西维来司他钠 山东新时代药业有限公司 3 CYHS2601944 普罗布考片 浙江江北药业有限公司 3 CYHS2601948 注射用盐酸兰地洛尔 海南灵康制药有限公司 3 CYHS2601949 硫酸特布他林口服溶液 上海美优制药有限公司 3 CYHS2601951 硫酸氨基葡萄糖胶囊 黑龙江亿达鸿药业有限公司 4 CYHS2602015 注射用多种维生素(12) 海南斯达制药有限公司 4 CYHS2602014 注射用磷酸左奥硝唑酯二钠 吉林敖东药业集团延吉股份有限公司 4 CYHS2602013 巴瑞替尼片 上海上药中西制药有限公司 4 CYHS2602021 多替诺雷片 湖南千金协力药业有限公司 4 CYHS2602019 普托马尼片 中诺凯琳健康产业(海南)有限公司 4 CYHS2602022 乳果糖口服溶液 浙江国镜药业有限公司 4 CYHS2601987 蛋白琥珀酸铁口服溶液 湖北长联杜勒制药有限公司 4 CYHS2601999 比拉斯汀片 宁波美诺华天康药业有限公司 4 CYHS2601998 左氧氟沙星滴眼液 西藏安星医药有限公司 4 CYHS2601996 左氧氟沙星滴眼液 西藏安星医药有限公司 4 CYHS2601995 布瑞哌唑片 山东信谊制药有限公司 4 CYHS2601991 布瑞哌唑片 山东信谊制药有限公司 4 CYHS2601990 布瑞哌唑片 山东信谊制药有限公司 4 CYHS2601989 盐酸阿莫罗芬搽剂 杭州万邦天诚药业有限公司 4 CYHS2602002 盐酸达泊西汀片 植恩生物技术股份有限公司 4 CYHS2602001 阿法骨化醇滴剂 青松(天津)制药有限公司 4 CYHS2602000 莫匹罗星软膏 浙江华海药业股份有限公司 4 CYHS2602010 醋酸地非法林注射液 甘李药业山东有限公司 4 CYHS2602009 注射用醋酸卡泊芬净 重庆药友制药有限责任公司 4 CYHS2602005 注射用醋酸卡泊芬净 重庆药友制药有限责任公司 4 CYHS2602004 达格列净片 重庆药友制药有限责任公司 4 CYHS2602007 达格列净片 重庆药友制药有限责任公司 4 CYHS2602006 苯磺酸左氨氯地平片 苏州特瑞药业股份有限公司 4 CYHS2602003 注射用磷酸左奥硝唑酯二钠 长春澜江医药科技有限公司 4 CYHS2601994 注射用磷酸左奥硝唑酯二钠 长春澜江医药科技有限公司 4 CYHS2601993 伊班膦酸钠注射液 长春澜江医药科技有限公司 4 CYHS2601974 伊班膦酸钠注射液 长春澜江医药科技有限公司 4 CYHS2601973 多种微量元素注射液(III) 辽宁海思科制药有限公司 4 CYHS2601986 苯磺酸美洛加巴林片 宜昌人福药业有限责任公司 4 CYHS2601981 苯磺酸左氨氯地平片 河北龙海药业股份有限公司 4 CYHS2601972 苯磺酸左氨氯地平片 河北龙海药业股份有限公司 4 CYHS2601971 硫酸氨基葡萄糖胶囊 湖北蝴蝶兰药业有限公司 4 CYHS2601977 注射用头孢呋辛钠/氯化钠注射液 海南倍特药业有限公司 4 CYHS2601970 氧(液态) 金川集团镍钴股份有限公司 4 CYHS2601969 吸入用布地奈德混悬液 海南斯达制药有限公司 4 CYHS2601967 阿奇霉素干混悬剂 山东鲁抗医药集团赛特有限责任公司 4 CYHS2601965 达格列净二甲双胍缓释片(I) 山东诚创蓝海医药科技有限公司 4 CYHS2601960 注射用氨曲南阿维巴坦钠 成都通德药业有限公司 4 CYHS2601942 塞来昔布胶囊 陕西西岳制药有限公司 4 CYHS2601941 磷/碳酸氢钠血滤置换液 山东华茂药业有限公司 4 CYHS2601940 阿法骨化醇软胶囊 青岛双鲸药业股份有限公司 4 CYHS2601939 达格列净片 浙江江北药业有限公司 4 CYHS2601938 达格列净片 浙江江北药业有限公司 4 CYHS2601937 乌帕替尼缓释片 江西施美药业股份有限公司 4 CYHS2601947 盐酸来罗西利片 亿腾医药(珠海)有限公司 4 CYHS2601946 盐酸阿莫罗芬搽剂 江苏晨牌邦德药业有限公司 4 CYHS2601945 洛索洛芬钠贴剂 湖南派格兰药业有限公司 4 CYHS2601943 沙美特罗替卡松吸入气雾剂 长风药业股份有限公司 4 CYHS2601954 达格列净二甲双胍缓释片(I) 陕西旭昂生物药业有限公司 4 CYHS2601952 蛋白琥珀酸铁口服溶液 湖南华纳大药厂股份有限公司 4 CYHS2601950 乳果糖口服溶液 江西施美药业股份有限公司 4 CYHS2601959 艾普拉唑肠溶片 广东安诺药业股份有限公司 4 CYHS2601958 盐酸西替利嗪滴剂 成都澜锦医药科技有限公司 4 CYHS2601957 盐酸西替利嗪滴剂 成都澜锦医药科技有限公司 4 CYHS2601956 戊酸雌二醇片 山东齐都药业有限公司 4 CYHS2601955 注射用磷酸左奥硝唑酯二钠 苏州天马医药集团天吉生物制药有限公司 4 CYHS2601953 替比培南匹伏酯细粒剂 上海则正医药科技股份有限公司 3 CYHL2600087 注射用TKB02 安徽泰恩康生物工程有限公司 3.3 CXSL2600853 AK2401注射液 安徽安科生物工程(集团)股份有限公司 3.3 CXSL2600850 进口申请 药品名称 企业 注册分类 受理号 非奈利酮片 Bayer AG 2.4 JXHS2600089 非奈利酮片 Bayer AG 2.4 JXHS2600088 比拉斯汀口崩片 Menarini International Operations Luxembourg S.A. 5.1 JXHS2600090 氯硝西泮片 CHEPLAPHARM Arzneimittel GmbH 5.1 JXHS2600087 阿柏西普眼内注射溶液 Bayer AG 3.1 JXSS2600073 磷酸芦可替尼片 MSN LABORATORIES PRIVATE LIMITED 5.2 JYHS2600015 LY4257496注射液 Eli Lilly and Company 1 JXHL2600339 RO7795068注射液 F. Hoffmann-La Roche Ltd 1 JXHL2600345 RO7795068注射液 F. Hoffmann-La Roche Ltd 1 JXHL2600344 RO7795068注射液 F. Hoffmann-La Roche Ltd 1 JXHL2600343 RO7795068注射液 F. Hoffmann-La Roche Ltd 1 JXHL2600342 RO7795068注射液 F. Hoffmann-La Roche Ltd. 1 JXHL2600341 RO7795068注射液 F. Hoffmann-La Roche Ltd 1 JXHL2600340 ETX-636 Ensem Therapeutics, Inc. 1 JXHL2600336 ETX-636 Ensem Therapeutics, Inc. 1 JXHL2600335 Venglustat Sanofi-Aventis Recherche & Developpement 1 JXHL2600333 Venglustat Sanofi-Aventis Recherche & Developpement 1 JXHL2600332 Rilzabrutinib微片 Sanofi-Aventis Recherche & Developpement 2.2;2.4 JXHL2600337 Rilzabrutinib片 Sanofi-Aventis Recherche & Developpement 2.4 JXHL2600338 AZD9833片 ASTRAZENECA AB 2.4 JXHL2600334 PG4 Pfizer Inc. 1.4 JXSL2600189 zenagamtide注射液 Novo Nordisk A/S 1 JXSL2600200 zenagamtide注射液 Novo Nordisk A/S 1 JXSL2600199 zenagamtide注射液 Novo Nordisk A/S 1 JXSL2600198 zenagamtide注射液 Novo Nordisk A/S 1 JXSL2600197 zenagamtide注射液 Novo Nordisk A/S 1 JXSL2600196 zenagamtide注射液 Novo Nordisk A/S 1 JXSL2600195 zenagamtide注射液 Novo Nordisk A/S 1 JXSL2600194 Verve-102注射液 Eli Lilly and Company 1 JXSL2600193 RO7589655注射液 F. Hoffmann-La Roche Ltd. 1 JXSL2600206 RO7589655注射液 F. Hoffmann-La Roche Ltd. 1 JXSL2600205 RO7589655注射液 F. Hoffmann-La Roche Ltd. 1 JXSL2600204 RO7589655注射液 F. Hoffmann-La Roche Ltd. 1 JXSL2600203 RO7589655注射液 F. Hoffmann-La Roche Ltd. 1 JXSL2600202 RO7589655注射液 F. Hoffmann-La Roche Ltd. 1 JXSL2600201 JNJ-79635322 Janssen Research & Development, LLC 1 JXSL2600192 JNJ-79635322 Janssen Research & Development, LLC 1 JXSL2600191 中药相关申请 药品名称 企业 注册分类 受理号 皮炎消颗粒 山西忻州兴华皮肤病专科医院 1.1 CXZL2600076 十味安肠颗粒 江苏康缘药业股份有限公司 1.1 CXZL2600075 CE-101 原研港(上海)中药科技有限公司 1.2 CXZL2600072 CE-201片 原研港(上海)中药科技有限公司 1.2 CXZL2600074 CE-201片 原研港(上海)中药科技有限公司 1.2 CXZL2600073 注射用正清风痛宁 湖南正清制药集团股份有限公司 2.1 CXZL2600071 真武汤颗粒 四环医药(郑州)有限公司 3.1 CXZS2600046 注：绿色字体部分为潜在首仿品种； 咸达数据2026年7月每月药讯已出！ 关注“咸达数据”，微信关键词回复 ” 年+月，如202606” 获得最新药迅！ 不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis Closed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runway into the second half of 2029 Appointed Debra Zack, M.D., Ph.D., as Chief Medical Officer Conference call today at 5pm EDT CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. "During the second quarter, we achieved several defining milestones that have fundamentally strengthened Spero's business. We entered the quarter as a company preparing for an important regulatory milestone and have since then announced the FDA approval of Utebzi; a new Phase 2-ready immunology program with SP001; and financing that positions us to continue executing on our mission to deliver transformative therapies to patients,” said Esther Rajavelu, President and Chief Executive Officer of Spero. "As we look to the remainder of 2026, our priorities are to advance SP001 toward a Phase 2 study in IgG4-related disease and continue evaluating additional development opportunities in immune-mediated diseases to expand the SP001 value proposition, while maintaining our disciplined approach to execution.” Recent Business Highlights Exclusive License Agreement with Innovent Biologics for SP001 ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); In July 2026, Spero entered into an exclusive license agreement with Innovent Biologics, Inc. for SP001. Spero gained exclusive rights to develop, research, manufacture, and commercialize SP001 worldwide, excluding Greater China (Mainland China, Hong Kong, Macau, and Taiwan), where Innovent retains rights. SP001 is a third-generation, fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L, an upstream immune activation signal involved in T-cell, B-cell, antigen-presenting cell, and platelet biology. Innovent completed two healthy volunteer Phase 1 trials, a single ascending dose (“SAD”) study and a multiple ascending dose (“MAD”) study, as well as a Phase 1b MAD study in patients with primary Sjögren’s disease (“SjD”). Data from the Phase 1b SjD study were presented in a poster session at the EULAR 2026 Congress. Spero plans to advance SP001 into a Phase 2 study in IgG4-related disease (IgG4-RD), a serious, rare chronic fibroinflammatory disease with significant treatment burden and limited therapeutic options. Utebzi (tebipenem pivoxil) U.S. FDA Approval In June 2026, Spero and GSK announced that the U.S. Food and Drug Administration (FDA) approved Utebzi for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment options. Utebzi is the first and only oral carbapenem antibiotic approved for these patients. The product is expected to be made available by GSK to U.S. patients by the end of 2026. GSK holds commercialization rights in the U.S. and Europe. $105 Million Non-Recourse, Non-Dilutive Royalty Financing In July 2026, Spero announced a non-recourse, non-dilutive royalty financing with affiliates of HealthCare Royalty Partners, a business of KKR (HCRx), for $105 million in gross proceeds, in exchange for rights to a portion of the anticipated payments from sales of Utebzi owing from GSK (GSK Proceeds). The transaction is structured as a non-recourse Note Purchase and Guaranty Agreement (NPA) generally payable solely from the GSK proceeds, and a Royalty and Milestone Payment Interest Purchase and Sale Agreement (RPA) under which the Company may retain 35% interest in the GSK Proceeds arising after required payments under the NPA, preserving potential long-term upside from the asset. The proceeds will primarily support advancement of SP001. Corporate In July 2026, Spero announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer. Dr. Zack is a board-certified rheumatologist with a Ph.D. in immunology and brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases. She will oversee Spero's clinical development strategy and organization as the Company advances its immunology program. Second Quarter 2026 Financial Results Spero reported a net loss of $9.6 million for the second quarter of 2026 compared to a net loss of $1.7 million for the second quarter of 2025, or a diluted net loss per share of common stock of $0.16 and $0.03, respectively. No revenue was recognized for the second quarter of 2026, compared to total revenue of $14.2 million for the second quarter of 2025, as all deferred revenue under the collaboration agreements was recognized in prior periods and all grant revenue has been fully recognized, and the awards have been completed and closed out. Research and development expenses for the second quarter of 2026 were $3.4 million, compared to $10.7 million of research and development expenses for the same period in 2025. The decrease in research and development expenses was a result of decreased clinical activities related to our pivotal Phase 3 clinical trial of Utebzi, which was stopped early for efficacy in the first half of 2025, and a decrease in personnel related costs. General and administrative expenses for the second quarter of 2026 were $6.5 million, compared to $5.9 million of general and administrative expenses for the same period in 2025. The increase was a result of increased legal and business development costs, offset partially by a decrease in personnel related costs. As of June 30, 2026, cash and cash equivalents were $50.8 million. This balance does not reflect the proceeds from the royalty financing completed in July 2026. The company expects that its cash and cash equivalents at June 30, 2026, together with the proceeds of the royalty financing, will be sufficient to fund operating expenses and capital expenditure into the second half of 2029. For further details on Spero’s financials, refer to Spero’s Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (SEC) today. Conference call and webcast Management will host a conference call and live audio webcast at 5:00 pm EDT today, August 12, to discuss the results and provide a business and pipeline update. To access the call, please dial 1-877-407-0789 (domestic) or 1-201-689-8562 (international) and refer to conference ID 13762082, or click on this link to request a return call. The webcast for the event can be accessed live on this link , or on the Investor Relations page of the Spero Corporate website at The archived webcast will be available for 30 days following the call. About SP001 SP001 is a third-generation, potential best-in-class, fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L, an upstream immune activation signal involved in T-cell, B-cell, antigen-presenting cell, and platelet biology. By blocking CD40L, SP001 has the potential to provide a targeted non-B-cell-depleting treatment across multiple immune-mediated diseases where immune-cell interactions drive chronic inflammation, relapse, and tissue damage. SP001 is designed to address platelet activation concerns associated with earlier anti-CD40L antibodies, while preserving key monoclonal antibody properties, including FcRn interaction that supports IgG-like half-life. About Spero Therapeutics Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, statements relating to Spero’s plans to advance SP001 into a Phase 2 study in IgG4-related disease; Spero’s plans to explore the use of SP001, and the role of CD40L inhibition, in additional autoimmune and inflammatory diseases; the anticipated benefits of the non-dilutive royalty-backed transaction, including the anticipated use of proceeds; Spero’s expectation that Utebzi will be made available to U.S. patients by the end of 2026; anticipated cash runway, and future milestones. Forward-looking statements are based on Spero’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to the completion and integration of the Innovent transaction; Spero’s ability to successfully develop SP001; the timing and outcome of clinical trials and regulatory interactions; the ability to obtain and maintain regulatory approvals; potential safety, efficacy, manufacturing, supply, intellectual property, financing, competitive, and market risks; and other risks described in Spero’s filings with the Securities and Exchange Commission. Spero undertakes no obligation to update any forward-looking statements, except as required by law. Investor Relations Contact: Shai Biran, PhD Spero Therapeutics IR@Sperotherapeutics.com Media Inquiries: media@sperotherapeutics.com Spero Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) June 30, December 31, 2026 2025 Cash and cash equivalents $ 50,774 $ 40,265 Other assets 1,992 28,654 Total assets $ 52,766 $ 68,919 Total liabilities 8,562 9,898 Total stockholder's equity 44,204 59,021 Total liabilities and stockholders' equity $ 52,766 $ 68,919 Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Revenues: Grant revenue $ — 2,387 $ — 3,150 Collaboration revenue - related party — 11,802 258 16,901 Collaboration revenue — — — 12 Total revenues — 14,189 258 20,063 Operating expenses: Research and development 3,434 10,672 6,343 24,278 General and administrative 6,492 5,878 11,379 12,702 Restructuring — 83 — 258 Total operating expenses 9,926 16,633 17,722 37,238 Loss from operations (9,926 ) (2,444 ) (17,464 ) (17,175 ) Total other income, net 374 744 709 1,609 Net loss $ (9,552 ) $ (1,700 ) $ (16,755 ) $ (15,566 ) Net loss per share attributable to common shareholders per share, basic and diluted $ (0.16 ) $ (0.03 ) $ (0.29 ) $ (0.28 ) Weighted average shares outstanding, basic and diluted: 57,968,608 56,026,767 57,626,986 55,703,275